Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

The woman wants to name her baby after her paternal grandmother, two years after her sister named her child after their ...

Eli Lilly is on Trump’s list as having committed $27 billion in investments. But that’s on top of an earlier commitment. In ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Directors of five NIH institutes have been placed on administrative leave or offered new assignments as part of sweeping HHS ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 ...

Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

European healthcare stocks tumble as Trump prepares new tariffs, with pharmaceutical firms bracing for economic fallout and market uncertainty.

Weil Gotshal & Manges partner Amy Rubin is joining Sidley Austin as co-head of its employee benefits and executive ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...